Document:

EX-4.5

 Exhibit 4.5 

AMENDED AND RESTATED 

OPTION AGREEMENT 
 This
Amended and Restated Option Agreement (this “Agreement”) is made and entered into as of this      day of             , 2017, by and among James McCarthy
and Richard Nathan (each, a “Grantor” and together, the “Grantors”) and Avon Road Partners, L.P. (the “Option Holder”). Terms used herein but not otherwise defined herein shall have the meanings
ascribed to them in that certain Option Agreement (the “Option Agreement”) by and among Grantors and Option Holder, dated as of March 16, 2016. 

WHEREAS, pursuant to the Option Agreement, the Option Holder previously purchased from each Grantor the right to purchase up to such number of
shares of the common stock, par value $0.0001 per share (“KSS Common Stock”), of KeyStone Solutions, Inc., a Delaware corporation (“KSS”), set forth opposite such Grantor’s name on Exhibit A attached
hereto and made a part hereof (with respect to each Grantor, the “KSS Option Shares”); 
 WHEREAS, KSS has entered into
that certain merger agreement (the “Merger Agreement”) by and among KSS, Novume Solutions, Inc., a Delaware corporation, Brekford Corp., a Delaware corporation, KeyStone Merger Sub, Inc., a Delaware corporation, and Brekford Merger
Sub, Inc., a Delaware corporation, dated as of February 10, 2017, pursuant to which, at the Effective Time (as defined in the Merger Agreement) each share of KSS Common Stock will be converted into and become exchangeable for the right to
receive 1.9399 shares of the common stock, par value $0.0001 per share (“Novume Common Stock”), of Novume Solutions, Inc., a Delaware corporation, which will, at the Effective Time, become the parent company of KSS; 

WHEREAS, Grantors and Option Holder desire amend and restate the Option Agreement as provided herein to, among other things, establish that,
at the Effective Time the Option Right shall cease to represent a right of Option Holder to acquire the KSS Option Shares and automatically be converted into a right of Option Holder to purchase shares of Novume Common Stock, up to such number as is
set forth opposite such Grantor’s name on Exhibit B attached hereto and made a part hereof (with respect to each Grantor, the “Novume Option Shares”).  

NOW, THEREFORE, in consideration of the foregoing and the mutual and dependent covenants hereinafter set forth, and for other due and valuable
consideration, the receipt and adequacy of which are hereby acknowledged, the parties agree as follows: 
 1. No Additional Consideration. Option
Holder is not required to pay any additional consideration to Grantors for the Option Right to purchase the Novume Option Shares. 
 2. Grant of Option
Right. 
 (a) Right to Purchase. Subject to the terms and conditions of this Agreement, at any time and from time to time on or
after the Effective Time and up to and including March 16, 2018 (the “Option Termination Date”), the Option Holder and its permitted assignees shall have the right (the “Option Right”), but not the obligation,
to cause each Grantor to sell some or all of such Grantor’s Novume Option Shares to the Option Holder and/or its permitted assignees at the Purchase Price (as defined in Section 3 of this Agreement). The Option Right
must be exercised simultaneously with respect to each Grantor on a pro rata basis based on the number of Novume Option Shares to be sold by each Grantor as set forth on Exhibit B and must be exercised with respect to at least twenty-five
percent (25%) of the Novume Option Shares to be sold by such Grantor. After the Option Termination Date, the Option Right shall expire and shall no longer be valid or exercisable. 

(b) Procedures. If the Option Holder and/or its permitted assignees desire to purchase the Novume Option Shares, and subject to the
full satisfaction of the condition precedent described in Section 2(c), the Option Holder and/or its permitted assignees shall, (i) on or before the Option Termination Date and on each occasion when the Option Holder
and/or its permitted assignees desire to exercise the Option Right, deliver to each Grantor a written notice (the “Option Exercise Notice”) exercising the Option Right and specifying the number of Novume Option

 
Shares to be purchased from each Grantor and, (ii) pay to each Grantor the Purchase Price in cash by check or wire transfer of immediately available funds applicable to the Option Shares to
be purchased from each such Grantor, to be held in escrow by each such Grantor until each Grantor shall execute and deliver to the Option Holder and/or its permitted assignees a stock power transferring to the Option Holder and/or its permitted
assignees the number of Novume Option Shares purchased from such Grantor in such exercise, free and clear of all liens, claims, pledges, hypothecations or encumbrances (including all options, rights of first refusal and similar rights)
(collectively, “Liens”) except (1) for liens, claims or encumbrances arising by virtue of any action or inaction by the Option Holder and/or its permitted assignees.  

3. Purchase Price. In the event the Option Holder and/or its permitted assignees exercise the Option Right hereunder, the purchase price at which the
Grantors shall be required to sell the Novume Option Shares (the “Purchase Price”) shall be equal to $1.00 per Novume Option Share. 
 4.
Retention of Option Shares. Prior to the earlier of the exercise of the Option Right or the Option Termination Date, each Grantor agrees to retain the Option Shares held by such Grantor free and clear of all Liens and not to enter into any
agreement restricting the transfer of such Grantor’s Option Shares except in each case as may arise under applicable securities laws and/or the Stockholders’ Agreement. 

5. Notices. Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient upon receipt, when delivered
personally or by courier, overnight delivery service or confirmed facsimile, or 48 hours after being deposited in the U.S. mail as certified or registered mail with postage prepaid, if such notice is addressed to the party to be notified at such
party’s address or facsimile number as set forth below or as subsequently modified by written notice. 
 If to James McCarthy: 

With a Copy To: 
 Morris DeFeo

 Crowell & Moring LLP 

1001 Pennsylvania Avenue NW 

Washington, D.C. 20004 
 If to
Richard Nathan: 
 With a Copy To: 

Morris DeFeo 
 Crowell &
Moring LLP 
 1001 Pennsylvania Avenue NW 

Washington, D.C. 20004 
 If to
Avon Road Partners, L.P.: 
 With a Copy To: 

Stoloff & Silver, LLP 

Attn: Gary D. Silver 
 26 Hamilton
Avenue – P.O. Box 1129 
 Monticello, New York 12701 

 7. Entire Agreement. This Agreement constitutes the sole and entire agreement of the parties to this
Agreement with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. 

8. Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs,
administrators, personal representatives, successors and permitted assigns. Neither this Agreement nor any of the rights of the parties hereunder may be transferred or assigned by any party hereto without the prior written consent of the other party
hereto, which may be withheld in the absolute discretion of such party for any reason or no reason; notwithstanding the foregoing, all or a portion of the rights of the Option Holder may be assigned, from time to time, to Robert Berman. Any
attempted transfer or assignment in violation of this Section 8 shall be null and void ab initio. 
 9. No Third-Party
Beneficiaries. This Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other person any legal or equitable
right, benefit or remedy of any nature whatsoever, under or by reason of this Agreement. 
 10. Titles and Headings. The Article, Section and
Paragraph titles and headings contained in this Agreement are inserted only as a matter of convenience and for ease of reference and in no way define, limit, extend or proscribe the scope of this Agreement or the intent or content of any provision
hereof. All references to sections, articles, schedules or exhibits contained herein mean sections, articles, schedules or exhibits of this Agreement unless otherwise stated. 

11. Amendment and Modification; Waiver. This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party
hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in
exercising, any rights, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or
further exercise thereof or the exercise of any other right, remedy, power or privilege. 
 12. Severability. If any provision of this Agreement is
held invalid or unenforceable, such decision shall not affect the validity or enforceability of any other provision of this Agreement, all of which other provisions shall remain in full force and effect. 

13. Choice of Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to
any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. 

14. Jurisdiction and Venue. Each of the Option Holder and the Grantors irrevocably consents to the exclusive jurisdiction and venue of any court within
Fairfax County, Virginia, in connection with any matter based upon or arising out of this Agreement or the matters contemplated herein, and agrees that process may be served upon them in any manner authorized by the laws of the Commonwealth of
Virginia for such persons. 
 15. Waiver of Jury Trial. Each party acknowledges and agrees that any controversy which may arise under this Agreement
is likely to involve complicated and difficult issues and, therefore, each such party irrevocably and unconditionally waives any right it may have to a trial by jury in respect of any legal action arising out of or relating to this Agreement or the
transactions contemplated hereby. 
 16. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but
all of which shall together be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same
legal effect as delivery of an original signed copy of this Agreement. 

 17. Further Assurances. Each party hereto shall timely execute and deliver any and all additional
documents, instruments, notices, and other assurances, and shall do any and all acts and things reasonably necessary in connection with the performance of their obligations hereunder and to carry out the intent of the parties hereto. 

[SIGNATURE PAGE FOLLOWS] 

 IN WITNESS WHEREOF, the parties hereto have executed this Amended and Restated Option Agreement
on the date first written above. 
  

			
	  

	James McCarthy
	
	  

	Richard Nathan
	
	Avon Road Partners, L.P.
		
	By:	 	                                      
                                        

	Robert Berman

  
 [Signature Page to
Amended and Restated Option Agreement] 

 Exhibit A 

KSS Option Shares 
  

					
	 Grantor
	  	Option Shares	 
	 James McCarthy
	  	 	1,405,110	 
	 Richard Nathan
	  	 	821,168	 

 Exhibit B 

Novume Option Shares 
  

					
	 Grantor
	  	Option Shares	 
	 James McCarthy
	  	 	2,725,773	 
	 Richard Nathan
	  	 	1,592,984EX-4.9

 Exhibit 4.9 

WARRANT TO PURCHASE SHARES OF COMMON STOCK 

OF 
 NOVUME SOLUTIONS, INC. 

1.    Issuance. In consideration of good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged by NOVUME SOLUTIONS, INC., a Delaware corporation (the “Company”),                     , a
                     company or its registered or permitted assigns (the “Holder”), is hereby granted the right to purchase at any
time on or after the Issue Date (as defined below) until the date which is the last calendar day of the month in which the fifth anniversary of the Issue Date occurs (the “Expiration Date”), 52,000 fully paid and nonassessable
shares (the “Warrant Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), as such number of Warrant Shares may be adjusted from time to time pursuant to the terms and
conditions of this Warrant to Purchase Shares of Common Stock (this “Warrant”). 
 This Warrant is issued to the Holder pursuant to and is
subject to the terms and conditions of the Merger Agreement by and among the Company, Brekford Traffic Safety, Inc., fka Brekford Corp., a Delaware corporation (“Brekford”), KeyStone Solutions, Inc., a Delaware corporation, and the
other parties named therein dated as of February 10, 2017 (the “Merger Agreement”). Upon the closing of the Merger Agreement (“Closing”), Brekford became a wholly-owned subsidiary of the Company. As part of the
merger consideration therefor, among other things, the Holder received this Warrant in exchange for a warrant to purchase shares of the common stock of Brekford, originally issued to the Holder that certain Note and Warrant Purchase Agreement, dated
as of March 17, 2015 (the “Purchase Agreement”) between Brekford and Holder. As of the Closing, this Warrant and the Warrant Shares are registered with the U.S. Securities and Exchange Commission (the “SEC”) on
a Registration Statement on Form S-4 (the “Registration Statement”), which became effective as of [●], 2017; however, this registration will be subject at all times to the continued
effectiveness of such Registration Statement. Capitalized terms used herein and not otherwise defined shall have the definitions ascribed to such terms in the Merger Agreement. 

2.    Exercise of Warrant. 

2.1.    General. 

(a)    This Warrant is exercisable in whole or in part at any time and from time to time commencing on the Issue Date and
ending on the Expiration Date. Such exercise shall be effectuated by submitting to the Company (either by delivery to the Company or by email or facsimile transmission) a completed and duly executed Notice of Exercise substantially in the form
attached to this Warrant as Exhibit A (the “Notice of Exercise”). The date such Notice of Exercise is either faxed, emailed or delivered to the Company shall be the “Exercise Date,” provided that, if such
exercise represents the full exercise of the outstanding balance of the Warrant, the Holder shall tender this Warrant to the Company within five (5) Trading Days thereafter, but only if the Warrant Shares to be delivered pursuant to the Notice
of Exercise have been delivered to the Holder as of such date. The Notice of Exercise shall be executed by the Holder and shall indicate (i) the number of Warrant Shares (as defined below) to be issued pursuant to such exercise, and
(ii) if applicable (as provided below), whether the exercise is a cashless exercise. 
 For purposes of this Warrant, the term
“Trading Day” means any day during which the principal market on which the Common Stock is traded (the “Principal Market”) shall be open for business. 

  
 1 

 (b)    If at any time there is no then effective Registration Statement
registering, or no then current prospectus available for, the resale of the Warrant Shares by the Holder, then to the extent this Warrant is not previously exercised, and if the Market Price of one Warrant Share is greater than the Exercise Price,
the Holder may elect to receive Warrant Shares, in lieu of a cash exercise, equal to the value of this Warrant determined in the manner described below (or of any portion thereof remaining unexercised) by surrender of this Warrant and a Notice of
Exercise, in which event the Company shall issue to Holder a number of Shares computed using the following formula: 
 X = Y (A-B) 
        A 

 

					
	Where  	  	X =	  	the number of Warrant Shares to be issued to Holder.
			
		  	Y =	  	the number of Warrant Shares that the Holder elects to purchase under this Warrant (at the date of such calculation).
			
		  	A =	  	the Market Price (at the date of such calculation).
			
		  	B =	  	Exercise Price (as adjusted to the date of such calculation).

 For the purposes of this Warrant, the following terms shall have the following meanings: 

“Affiliate” shall mean an affiliate as such term is defined in Rule 144 under the Securities Act of 1933, as amended (or a
successor rule). 
 “Aggregate Exercise Price Payable” shall mean the product of multiplying the number of Warrant Shares
exercisable by the Exercise Price. 
 “Closing Price” shall mean the 4:00 P.M. last sale price of the Common Stock on the
Principal Market on the relevant Trading Day(s), as reported by Bloomberg LP (or if that service is not then reporting the relevant information regarding the Common Stock, a comparable reporting service of national reputation selected by the Holder
and reasonably acceptable to the Company) (“Bloomberg”) for the relevant date. 
 “Common Stock
Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at
any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive Common Stock. 

“Exercise Price” shall mean $7.50 per share of Common Stock, subject to adjustments herein. 

“Issue Date” shall mean March 17, 2015. 

“Market Price” shall mean the Closing Price for the Common Stock on the Trading Day that is two Trading Days prior to the
Exercise Date. 
 “Note” shall mean that certain 6% Convertible Note issued by the Company to the Holder on the Issue Date
pursuant to the Purchase Agreement, as the same may be amended from time to time, and including any note(s) that replace or are exchanged for such referenced note. 

  
 2 

 (c)    If the Notice of Exercise form elects a “cash” exercise (or
if the cashless exercise referred to in the immediately preceding subsection (b) is not available in accordance with the terms hereof), the Exercise Price per share of Common Stock for the Warrant Shares shall be payable, at the election of the
Holder, in cash or by certified or official bank check or by wire transfer in accordance with instructions provided by the Company at the request of the Holder. 

(d)    Upon the appropriate payment to the Company, if any, of the Exercise Price for the Warrant Shares, together with
the surrender of this Warrant (if required), the Company shall promptly, but in no case later than the date that is three (3) Trading Days following the date the Exercise Price is paid to the Company (or with respect to a “cashless
exercise,” the date that is three (3) Trading Days following the Exercise Date) (the “Delivery Date”), provided that all DWAC eligible conditions are then satisfied, deliver or cause the Company’s Transfer Agent to
deliver the applicable Warrant Shares electronically via the Deposit/Withdrawal at Custodian (“DWAC”) system to the account designated by the Holder on the Notice of Exercise. If all DWAC eligible conditions are not then satisfied,
the Company shall instead issue and deliver or cause to be issued and delivered (via reputable overnight courier) to the address as specified in the Notice of Exercise, a certificate, registered in the name of the Holder or its designee, for the
number of Warrant Shares to which the Holder shall be entitled. For the avoidance of doubt, the Company has not met its obligation to deliver Warrant Shares by the Delivery Date unless the Transfer Agent has posted the shares for DWAC pickup and the
Holder or its broker, as applicable, has been notified of this availability, or if the DWAC eligible conditions are not then satisfied, has actually received the certificate representing the applicable Warrant Shares no later than the close of
business on the relevant Delivery Date pursuant to the terms set forth above. Notwithstanding the foregoing, any certificate or certificates representing the Warrant Shares to be issued without any restrictive legend on or prior to a Delivery Date
may only be done in connection with a bona fide sale of such securities as a result of the requirements under Rule 144(i) promulgated under the Securities Act. 

(e)    If Warrant Shares are delivered later than as required under subsection (d) immediately above (other than as
a result of any request to deliver any such certificate(s) without a restrictive legend that is not in connection with a sale of such securities), the Company agrees to pay, in addition to all other remedies available to the Holder in the
Transaction Documents, a late charge equal to the greater of (i) $1,000.00 and (ii) 1% of the product of (1) the sum of the number of shares of Common Stock not issued to the Holder on a timely basis and to which the Holder is entitled
multiplied by (2) the Closing Price of the Common Stock on the Trading Day immediately preceding the last possible date which the Company could have issued such shares of Common Stock to the Holder without violating this Warrant, per Trading
Day until such Warrant Shares are delivered. The Company shall pay any late charges incurred under this subsection in immediately available funds upon demand. Furthermore, in addition to any other remedies which may be available to the Holder, in
the event that the Company fails for any reason to effect delivery of the Warrant Shares as required under subsection (d) immediately above, the Holder may revoke all or part of the relevant Warrant exercise by delivery of a notice to such
effect to the Company, whereupon the Company and the Holder shall each be restored to their respective positions immediately prior to the exercise of the relevant portion of this Warrant, except that the late charge described above shall be payable
through the date notice of revocation or rescission is given to the Company. 
 (f)    The Holder shall be deemed to be
the holder of the Warrant Shares issuable to it in accordance with the provisions of this Section 2.1 on the Exercise Date. 

2.2.    Ownership Limitation. If at any time, upon exercise of the Warrant, the Buyer would, together with other
shares of Common Stock held by it or its Affiliates, own or beneficially own by virtue of such action or receipt of additional shares of Common Stock a number of shares exceeding 

  
 3 

 
9.99% of the number of shares of Common Stock outstanding on such date (the “Maximum Percentage”), the Company shall not be obligated and shall not issue to the Buyer and the
Buyer shall not receive any shares of Common Stock which would exceed the Maximum Percentage, but only until such time as the Maximum Percentage would no longer be exceeded by any such receipt of shares of Common Stock by the Buyer. The foregoing
limitations are enforceable, unconditional and non-waivable and shall apply to all Affiliates and assigns of the Buyer. 

3.    Mutilation or Loss of Warrant. Upon receipt by the Company of evidence satisfactory to it of the loss, theft,
destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) receipt of reasonably satisfactory indemnification, and (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will execute
and deliver to the Holder a new Warrant of like tenor and date and any such lost, stolen, destroyed or mutilated Warrant shall thereupon become void. 

4.    Rights of the Holder. The Holder shall not, by virtue of this Warrant alone, be entitled to any rights of a
stockholder in the Company, either at law or in equity, and the rights of the Holder with respect to or arising under this Warrant are limited to those expressed in this Warrant and are not enforceable against the Company except to the extent set
forth herein. 
 5.    Certain Adjustments. 

5.1.    Capital Adjustments. If the Company shall at any time prior to the expiration of this Warrant subdivide the
Common Stock, by split-up or stock split, or otherwise, or combine its Common Stock, or issue additional shares of its Common Stock as a dividend, the number of Warrant Shares issuable upon the exercise of
this Warrant shall forthwith be automatically increased proportionately in the case of a subdivision, split or stock dividend, or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the Exercise
Price, Market Price (in the event of a cashless exercise), and other applicable amounts, but the aggregate purchase price payable for the total number of Warrant Shares purchasable under this Warrant (as adjusted) shall remain the same. Any
adjustment under this Section 5.1 shall become effective automatically at the close of business on the date the subdivision or combination becomes effective, or as of the record date of such dividend, or in the event that no record date is
fixed, upon the making of such dividend. 
 5.2.    Reclassification, Reorganization and Consolidation. In case
of any reclassification, capital reorganization, or change in the capital stock of the Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section 5.1 above), then the Company shall make appropriate
provision so that the Holder shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of stock and other securities
and property receivable in connection with such reclassification, reorganization, or change by a holder of the same number of shares of Common Stock as were purchasable by the Holder immediately prior to such reclassification, reorganization, or
change. In any such case appropriate provisions shall be made with respect to the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities and property
deliverable upon exercise hereof, and appropriate adjustments shall be made to the purchase price per Warrant Share payable hereunder, provided the aggregate purchase price shall remain the same. 

5.3.    Dilutive Issuances. If the Company, at any time while this Warrant is outstanding, shall sell or grant any
option to purchase, or sell or grant any right to re-price, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common Stock
Equivalents entitling any Person to acquire shares of Common Stock, at an effective price per share less than the then Exercise Price (such lower price, the “Base Share Price” 

  
 4 

 
and such issuances collectively, a “Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of
purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common
Stock at an effective price per share which is less than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price on such date of the Dilutive Issuance), then the Exercise Price shall be reduced and only
reduced to equal the Base Share Price and the number of Warrant Shares issuable hereunder shall be increased such that the Aggregate Exercise Price Payable hereunder, after taking into account the decrease in the Exercise Price, shall be equal to
the Aggregate Exercise Price prior to such adjustment. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued. Notwithstanding the foregoing, no adjustments shall be made, paid or issued under this
Section 5.3 in respect to Exempt Issuances. For purposes of this Section, “Exempt Issuances” means the issuance of (a) shares of Common Stock or options to employees, officers, directors, consultants or collaborators of
the Company pursuant to any stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or
convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that the terms of such securities are not amended or changed after the date hereof, (c) securities issued pursuant to commercial
collaborations, acquisitions or strategic transactions approved by a majority of the disinterested directors whose primary purpose is not to raise capital (d) securities issued in connection with any bona fide commercial loan or debt
transaction with third persons, provided that the primary purpose of such transaction is not to raise equity capital and is approved by the Company’s Board of Directors in good faith, (e) any Permitted Subordinated Indebtedness or
(f) any Dilutive Issuance in any amount less than $25,000. The Company shall notify the Holder in writing, no later than three Trading Days following the issuance of any Common Stock or Common Stock Equivalents subject to this Section 5.3,
indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice the “Dilutive Issuance Notice”). For purposes of clarification, whether or not the
Company provides a Dilutive Issuance Notice pursuant to this Section 5.3, upon the occurrence of any Dilutive Issuance, after the date of such Dilutive Issuance the Holder is entitled to receive a number of Warrant Shares based upon the Base
Share Price regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise. Without limiting any other provision contained herein, when any adjustment is required to be made in the number or kind of shares
purchasable upon exercise of this Warrant, or in the Exercise Price, pursuant to the terms hereof, the Company shall promptly notify the Holder of such event and of the number of Warrant Shares or other securities or property thereafter purchasable
upon exercise of this Warrant. 
 6.    Certificate as to Adjustments. In each case of any adjustment or
readjustment in the shares of Common Stock issuable on the exercise of this Warrant, the Company at its expense will promptly cause its Chief Financial Officer or other appropriate designee to compute such adjustment or readjustment in accordance
with the terms of this Warrant and prepare a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based, including a statement of (a) the number of shares of
Common Stock outstanding or deemed to be outstanding, and (b) the Exercise Price and the number of shares of Common Stock to be received upon exercise of this Warrant, in effect immediately prior to such adjustment or readjustment and as
adjusted or readjusted as provided in this Warrant. The Company will forthwith mail a copy of each such certificate to the Holder and any Warrant Agent (as defined below) appointed pursuant to Section 8 hereof. Nothing in this Section 6
shall be deemed to limit any other provision contained herein. 
 7.    Transfer to Comply with the Securities
Act. This Warrant, the Warrant Shares and any other security issued or issuable upon exercise of this Warrant may only be sold, transferred, pledged or 

  
 5 

 
hypothecated (other than to an Affiliate) if (a) there exists an then current effective registration statement under the Securities Act relating to such security or (b) the Company has
received an opinion of counsel reasonably satisfactory to the Company that registration is not required under the Securities Act. At any time if there is no such then current registration statement under the Securities Act, each certificate for this
Warrant, the Warrant Shares and any other security issued or issuable upon exercise of this Warrant shall contain a legend, in form and substance satisfactory to counsel for the Company, setting forth the restrictions on transfer contained in this
Section 7. Any such transfer shall be accompanied by a transferor assignment substantially in the form attached to this Warrant as Exhibit B (the “Transferor Assignment”), executed by the transferor and the transferee
and submitted to the Company. Upon receipt of the duly executed Transferor Assignment, the Company shall register the transferee thereon as the new Holder on the books and records of the Company and such transferee shall be deemed a “registered
holder” or “registered assign” for all purposes hereunder, and shall have all the rights of the Holder. 

8.    Warrant Agent. The Company may, by written notice to the Holder, appoint an agent (a “Warrant
Agent”) for the purpose of issuing shares of Common Stock on the exercise of this Warrant pursuant hereto, exchanging this Warrant pursuant hereto, and replacing this Warrant pursuant hereto, or any of the foregoing, and thereafter any such
issuance, exchange or replacement, as the case may be, shall be made at such office by such Warrant Agent. 

9.    Transfer on the Company’s Books. Until this Warrant is transferred on the books of the Company, the
Company may treat the Holder as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. 

10.    Notices. Any notice required or permitted hereunder shall be given at the addresses of the Company and the
Holder indicated on the signature page hereto. 
 11.    Supplements and Amendments; Whole Agreement. This
Warrant may be amended or supplemented only by an instrument in writing signed by the parties hereto. This Warrant, together with the Purchase Agreement and all the other Transaction Documents, taken together, contain the full understanding of the
parties hereto with respect to the subject matter hereof and thereof and there are no representations, warranties, agreements or understandings with respect to the subject matter hereof and thereof other than as expressly contained herein and
therein. 
 12.    Governing Law. This Warrant shall be governed by and interpreted in accordance with the laws
of the State of California, without giving effect to the principles thereof regarding the conflict of laws. The Company and, by accepting this Warrant, the Holder, each irrevocably (a) consent to and expressly submit to the exclusive personal
jurisdiction of any state or federal court sitting in San Diego County, California in connection with any dispute or proceeding arising out of or relating to this Warrant, (b) agree that all claims in respect of any such dispute or proceeding
may only be heard and determined in any such court, (c) expressly submit to the venue of any such court for the purposes hereof, and (d) waive any claim of improper venue and any claim or objection that such courts are an inconvenient
forum or any other claim or objection to the bringing of any such proceeding in such jurisdictions or to any claim that such venue of the suit, action or proceeding is improper. The Company and, by accepting this Warrant, the Holder, each hereby
irrevocably consent to the service of process of any of the aforementioned courts in any such proceeding by the mailing of copies thereof by reputable overnight courier (e.g., FedEx) or certified mail, postage prepaid, to such party’s address
as provided for herein, such service to become effective ten (10) calendar days after such mailing. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY. 

  
 6 

 13.    Remedies. The remedies at law of the Holder of this Warrant in
the event of any default or threatened default by the Company in the performance of or compliance with any of the terms of this Warrant are not and will not be adequate and, without limiting any other remedies available to the Holder at law or in
equity, to the fullest extent permitted by law, such terms may be specifically enforced by a decree for the specific performance of any agreement contained herein or by an injunction against a violation of any of the terms hereof or otherwise. 

14.    Counterparts. This Warrant may be executed in any number of counterparts and each of such counterparts shall
for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. Signature delivered via facsimile or email shall be considered original signatures for purposes hereof. 

15.    Descriptive Headings. Descriptive headings of the sections of this Warrant are inserted for convenience only
and shall not control or affect the meaning or construction of any of the provisions hereof. 

16.    Attorney’s Fees. In the event of any litigation or dispute arising from this Warrant, the parties agree
that the party who is awarded the most money shall be deemed the prevailing party for all purposes and shall therefore be entitled to an additional award of the full amount of the attorneys’ fees and expenses paid by said prevailing party in
connection with the litigation and/or dispute without reduction or apportionment based upon the individual claims or defenses giving rise to the fees and expenses. Nothing herein shall restrict or impair a court’s power to award fees and
expenses for frivolous or bad faith pleading. 
 17.    Severability. Whenever possible, each provision of this
Warrant shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be invalid or unenforceable in any jurisdiction, such provision shall be modified to achieve the objective of
the parties to the fullest extent permitted and such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Warrant or the validity or enforceability of this Warrant in any other jurisdiction. 

[Remainder of page intentionally left blank] 

  
 7 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by an officer
thereunto duly authorized. 
 Dated:             , 2017 

 

			
	COMPANY:
	
	NOVUME SOLUTIONS, INC.
		
	By:	 	  

	Name:	 	Robert A. Berman
	Title:	 	Chief Executive Officer

  

			
	Address:	 	14420 Albemarle Point Place,
		 	Suite 200, Chantilly, VA 20151
		
	Copy To:	 	Morris DeFeo
		 	Crowell & Moring, LLP
		 	1001 Pennsylvania Avenue NW
		 	Washington, D.C. 20004

  

			
	Accepted and agreed,
	
	HOLDER:

			
		
	 By:
	 	  

	 Name:

	
	 Address:

 EXHIBIT A 

NOTICE OF EXERCISE OF WARRANT 
  

	TO:	NOVUME SOLUTIONS, INC. 

 ATTN:
                                         

 VIA FAX TO:
(    )                                   

VIA EMAIL TO:
(    )                              

The undersigned hereby irrevocably elects to exercise the right, represented by the Warrant to Purchase Shares of Common Stock dated as of
March 17, 2015 (the “Warrant”), to purchase shares of the common stock, $0.0001 par value (“Common Stock”), of NOVUME SOLUTIONS, INC., and tenders herewith payment in accordance with Section 2 of the
Warrant, as follows: 
  

					
	
                
	  	 CASH:
$                                         
           = (Exercise Price x Warrant Shares)

		
	
                
	  	 Payment is being made by:

		  	                	  	enclosed check
		  	                	  	wire transfer
		  	                	  	other
		
	
                
	  	 CASHLESS EXERCISE:

		
		  	Net number of Warrant Shares to be issued to Holder:                  *

  
 * X = Y
(A-B) 
         A 

 

					
	Where	 	X =	  	the number of Warrant Shares to be issued to Holder.
			
		 	Y =	  	the number of Warrant Shares that the Holder elects to purchase under this Warrant (at the date of such calculation).
			
		 	A =	  	the Market Price (at the date of such calculation).
			
		 	B =	  	Exercise Price (as adjusted to the date of such calculation).

 Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the
Warrant. 
 It is the intention of the Holder to comply with the provisions of Section 2.2 of the Warrant regarding certain limits on
the Holder’s right to exercise thereunder. The Holder believes this exercise complies with the provisions of such Section 2.2. Nonetheless, to the extent that, pursuant to the exercise effected hereby, the Holder would have more shares of
Common Stock than permitted under Section 2.2, this notice should be amended and revised, ab initio, to refer to the exercise which would result in the issuance of the maximum number of such shares permitted under such provision. Any
exercise above such amount is hereby deemed void and revoked. 
 As contemplated by the Warrant, this Notice of Exercise is being sent by
facsimile or email to the fax number and officer indicated above. 

 If this Notice of Exercise represents the full exercise of the outstanding balance of the
Warrant, the Holder either ( l ) has previously surrendered the Warrant to the Company or (2) will surrender (or cause to be surrendered) the Warrant to the Company at the address indicated above by express courier within five (5) Trading
Days after delivery or email or facsimile transmission of this Notice of Exercise; provided that the Warrant Shares to be delivered pursuant to this Notice of Exercise have been delivered to the Holder as of such date. 

To the extent the Warrant Shares are not able to be delivered to the Holder via the DWAC system, please deliver certificates representing the
Warrant Shares to the Holder via reputable overnight courier after receipt of this Notice of Exercise (by facsimile transmission or otherwise) to: 
  

	
	  

	
	   

	
	  

  

			
	Dated:	 	  

			
	
	  

	[Name of Holder]

			
		
	By:	 	  

 EXHIBIT B 

FORM OF TRANSFEROR ENDORSEMENT 

(To be signed only on transfer of the Warrant) 

For value received, the undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading
“Transferees” the right represented by the Warrant to Purchase Shares of Common Stock dated as of March 17, 2015 (the “Warrant”) to purchase the percentage and number of shares of common stock, $0.0001 par value
(“Common Stock”), of NOVUME SOLUTIONS, INC. specified under the headings “Percentage Transferred” and “Number Transferred,” respectively, opposite the name(s) of such person(s), and appoints each such person
attorney to transfer the undersigned’s respective right on the books of NOVUME SOLUTIONS, INC. with full power of substitution in the premises. 

Transferees                       
          Percentage
Transferred                            Number Transferred 

Dated:                    
     ,                  
  

			
	  

	[Transferor Name must conform to the name of Holder as specified on the face of the Warrant]

 
			
		
	By:	 	  

	Name:	 	  

  

			
	Signed in the presence of:
	
	  

	(Name)
	
	ACCEPTED AND AGREED:
	
	  

	[TRANSFEREE]

			
		
	By:	 	  

	Name	 	  

  
 - 1 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]